Biosimilars — Total Revenue
Biogen Biosimilars — Total Revenue increased by 7.3% to $182.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.8%, from $180.80M to $182.20M. Over 4 years (FY 2021 to FY 2025), Biosimilars — Total Revenue shows a downward trend with a -3.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market adoption and competitive pricing strategies for biosimilar offerings, while a decrease may signal increased market competition or loss of exclusivity for key products.
Detailed definition
This metric represents the total gross revenue generated from the sale of biosimilar pharmaceutical products within the...
Peer comparison
Peers in the biopharmaceutical industry often report this as a distinct segment to highlight their transition into lower-cost biologic alternatives, with performance typically benchmarked against market share in specific therapeutic areas.
biib_segment_biosimilars_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $202.40M | $202.80M | $220.80M | $194.30M | $194.40M | $187.60M | $174.80M | $192.40M | $195.10M | $194.30M | $188.20M | $196.90M | $198.10M | $196.60M | $201.50M | $180.80M | $181.70M | $196.80M | $169.80M | $182.20M |
| QoQ Change | — | +0.2% | +8.9% | -12.0% | +0.1% | -3.5% | -6.8% | +10.1% | +1.4% | -0.4% | -3.1% | +4.6% | +0.6% | -0.8% | +2.5% | -10.3% | +0.5% | +8.3% | -13.7% | +7.3% |
| YoY Change | — | — | — | — | -4.0% | -7.5% | -20.8% | -1.0% | +0.4% | +3.6% | +7.7% | +2.3% | +1.5% | +1.2% | +7.1% | -8.2% | -8.3% | +0.1% | -15.7% | +0.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's biosimilars — total revenue?
- Biogen (BIIB) reported biosimilars — total revenue of $182.20M in Q1 2026.
- How has Biogen's biosimilars — total revenue changed year-over-year?
- Biogen's biosimilars — total revenue increased by 0.8% year-over-year, from $180.80M to $182.20M.
- What is the long-term trend for Biogen's biosimilars — total revenue?
- Over 4 years (2021 to 2025), Biogen's biosimilars — total revenue has grown at a -3.2% compound annual growth rate (CAGR), from $831.10M to $729.10M.
- What does biosimilars — total revenue mean?
- The total sales revenue generated from the company's portfolio of biosimilar drug products.